Published in Psychiatry Res on May 01, 1980
Choline: critical role during fetal development and dietary requirements in adults. Annu Rev Nutr (2006) 2.83
Choline and betaine in health and disease. J Inherit Metab Dis (2010) 1.61
Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome. Behav Neurosci (2010) 1.09
Improved human visuomotor performance and pupil constriction after choline supplementation in a placebo-controlled double-blind study. Sci Rep (2015) 0.80
Plasma 1-carbon metabolites and academic achievement in 15-yr-old adolescents. FASEB J (2016) 0.75
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology (1989) 16.83
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A (2001) 6.68
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology (1994) 5.81
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med (1998) 4.43
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry (2007) 3.44
Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA (1999) 3.22
Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol (1998) 3.20
A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology (2000) 2.76
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry (2001) 2.74
Evidence for a susceptibility gene for autism on chromosome 2 and for genetic heterogeneity. Am J Hum Genet (2001) 2.51
Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull (1988) 2.50
A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry (1994) 2.41
Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol (1992) 2.19
Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol (1999) 2.02
Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry (2000) 1.93
Distribution, propagation, and coordination of contractile activity in lymphatics. Am J Physiol (1993) 1.92
Patterns of risk in first-degree relatives of patients with Alzheimer's disease. Arch Gen Psychiatry (1994) 1.84
The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull (1983) 1.81
Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. Am J Psychiatry (1986) 1.80
Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry (1989) 1.79
A psychobiological perspective on the personality disorders. Am J Psychiatry (1991) 1.76
Genome scan of schizophrenia. Am J Psychiatry (1998) 1.74
Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol (1995) 1.69
Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology (2006) 1.68
Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry (1999) 1.62
Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology (2001) 1.61
Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry (1998) 1.60
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry (1996) 1.52
Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Arch Gen Psychiatry (1997) 1.51
The longitudinal stability of cognitive impairment in schizophrenia. Mini-mental state scores at one- and two-year follow-ups in geriatric in-patients. Br J Psychiatry (1995) 1.46
Deterioration on the Blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res (1992) 1.45
Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. Am J Psychiatry (2001) 1.43
Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem (1995) 1.41
Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry (1991) 1.41
Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry (1993) 1.39
Mechanisms of killing of spores of Bacillus subtilis by iodine, glutaraldehyde and nitrous acid. J Appl Microbiol (2000) 1.39
Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry (1998) 1.39
Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry (1999) 1.36
Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol (2000) 1.35
Familial aggregation in Alzheimer's disease: comparison of risk among relatives of early-and late-onset cases, and among male and female relatives in successive generations. Neurology (1988) 1.32
Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry (1985) 1.27
Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer's Disease. Neurology (1998) 1.26
Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr Res (2005) 1.24
Postmortem studies in schizophrenia. Schizophr Bull (1998) 1.23
Cortisol and Alzheimer's disease, I: Basal studies. Am J Psychiatry (1986) 1.20
Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry (1994) 1.19
Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol (2001) 1.17
Physostigmine: improvement of long-term memory processes in normal humans. Science (1978) 1.16
Alzheimer's disease. Morbid risk among first-degree relatives approximates 50% by 90 years of age. Arch Gen Psychiatry (1987) 1.16
Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol (2001) 1.15
Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry (2001) 1.14
Neuropsychological test performance in African-American and white patients with Alzheimer's disease. Neurology (1995) 1.14
Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology (1996) 1.13
The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. Compr Psychiatry (2001) 1.13
A study of the reliability of the family history method in genetic studies of Alzheimer disease. Alzheimer Dis Assoc Disord (1989) 1.13
Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene. Mol Psychiatry (2007) 1.12
Evidence of a locus for schizophrenia and related disorders on the short arm of chromosome 5 in a large pedigree. Am J Med Genet (1996) 1.12
AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology (2007) 1.10
The validity of the family history method for identifying Alzheimer disease. Arch Neurol (1997) 1.09
Genetic epidemiological study of maternal and paternal transmission of Alzheimer's disease. Am J Med Genet (1999) 1.09
Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Res (1992) 1.09
Reactive oxygen metabolites inhibit spontaneous lymphatic contractions. Am J Physiol (1991) 1.08
N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry (2001) 1.08
Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull (1988) 1.08
Lymphocyte function in major depressive disorder. Arch Gen Psychiatry (1984) 1.07
Physostigmine in mania. Arch Gen Psychiatry (1978) 1.07
Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res (1993) 1.07
Characteristics of very poor outcome schizophrenia. Am J Psychiatry (1987) 1.05
Age-related shift in brain region activity during successful memory performance. Neurobiol Aging (1999) 1.05
Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry (1997) 1.04
Affective and impulsive personality disorder traits in the relatives of patients with borderline personality disorder. Am J Psychiatry (1991) 1.04
Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A (1993) 1.03
Single case study. Possible organophosphate-induced parkinsonism. J Nerv Ment Dis (1978) 1.03